Effect Of L-Deprenyl On Nitric Oxide Metabolites In Parkinson?s Disease Patients
Sibel Altınayar*, Feriha Özer***, Yusuf Türköz**, Handan Işın Özışık*, Sibel Çetin***, Eyüp Altınöz**,Cemal Özcan*
Objectives: L-deprenyl is an irreversible mitochondrial monoamine oxidase type-B (MAO-B) inhibitor and is mostly
used in Parkinson’s Disease (PD) treatment. However, it is believed that the effect of L-deprenyl in PD is by a
different mechanism than MAO-B enzyme inhibition and may be due to several factors. Neuroprotective effect of
L-deprenyl on cerebral tissue achieved by NO production has been shown by in vivo and in vitro tissue studies. The
purpose of this study was to determine the level of nitric oxide (NO) metabolites, nitrite and nitrate in human
serum and to assess whether there is any relationship among serum nitrate–nitrite levels and L-deprenyl in PD.
Patients and Methods: Twenty-one patients used L-Deprenile and 16 patients did not. Twenty-four healthy age- and
sex matched control were included in the study. Serum total nitrite and nitrate levels were determined
Results: The levels of Total nitrite and Nitrate in L-Deprenil using and L-Deprenil not using, and control groups
were found to be 63.8±30.1 μmol/L and 67.3±29.0 μmol/L, 62.6±16.2 μmol/L and 59.5±16.2 μmol/L, 66.2±21.8
μmol/L and 62.4±21.2 μmol/L, respectively. Serum total nitrite and nitrate levels were not significantly different
among the three groups.
Conclusion: These data do not support the concept that neuroprotective effect of L-deprenyl on cerebral tissue is
achieved by NO production. Therefore, further in vivo and in vitro studies are needed to exactly clarify the cerebral
effects of L-deprenyl and the role of NO in patients with PD.
Key Words: Parkinson’s Disease; L-Deprenyl; Nitric Oxide; Total Nitrite; Nitrate.